Navigation Links
eBioscience Corporation Announced Today That James Glynn Has Been Appointed to Its Board of Directors, Effective April 15, 2008

SAN DIEGO, April 15 /PRNewswire/ -- Mr. Glynn has over 34 years of combined financial, operating and director level experience, and is well known within the life sciences industry for his role in the growth and development of several biotechnology companies. Most notably, Mr. Glynn retired from Invitrogen Corporation (Nasdaq: IVGN) in 2003 where, during his tenure with the company, he held several operating roles including CFO, President and COO and CEO. During this time, Mr. Glynn led the company through several stages of growth including an IPO, numerous financings and several acquisitions including Novex, GIBCO Life Technologies, Research Genetics and Molecular Probes. Mr. Glynn, following his retirement from Invitrogen Corporation, remained on the company's board of directors until April 2006.

"We are very pleased to be adding someone of Jim's reputation and experience to our board," said Todd R. Nelson Ph.D., eBioscience's Chief Executive Officer. "As an emerging global leader in the cellular analysis market, we are focused on growing our business operations through the development and commercialization of a diverse array of products, and also through the operational execution of several key strategic initiatives. In his role as director, Mr. Glynn will provide invaluable operating insight, financial advice and strategic guidance to ensure eBioscience remains a leader in the life sciences market place." Brian Seed Ph.D., Chairman of the board of directors for eBioscience added, "We look forward to tapping Jim's wealth of operating wisdom and the insights gleaned from his decades of senior management experience in the life science and related industries. Jim enjoys an enviable reputation among investors and professional fund managers for his business insight, strategic acumen, and proven ability to contribute guidance at the board level."

Prior to joining Invitrogen Corporation in 1998 as the company's CFO, Mr. Glynn served as CFO for Matrix Pharmaceutical, Inc. from 1995 to 1998 and as CFO for Mycogen Corporation from 1987 to 1995. Prior to that he was Vice President, Finance & Treasurer of Lubrizol Enterprises, Inc. and an Audit manager for Price Waterhouse & Co. from 1974 to 1982.

Mr. Glynn currently serves as a director for Alphatec Spine, Inc. and American Specialty Health.

SOURCE eBioscience Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
2. Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest
3. IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference
4. Sigma-Aldrich Corporation 1st Quarter 2008 Earnings Conference Call
5. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
6. Chem Rx Corporation Reports Full Year 2007 Financial Results
7. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
8. Genaera Corporation Announces 2007 Financial Results
9. Chem Rx Corporation Schedules Conference Call to Review Full Year 2007 Financial Results
10. Immunosyn Corporation Announces 2007 Results, Files 10KSB
11. Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36%
Post Your Comments:
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is one ... biomarkers market with pharmaceutical companies and diagnostic ... diagnostic tests. . ... Complete report on global cancer biomarkers market ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 ... cat and human plaque and pave the way for more ... problems in cats     --> ... most commonly diagnosed health problems in cats, yet relatively little ... now. Two collaborative studies have been conducted by researchers from ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
Breaking Biology Technology:
(Date:10/26/2015)... Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern authentication ... , today announced the launch of its latest version ... unified platform enabling organizations to use standards-based authentication that ... Nok Nok S3 Authentication Suite is ideal for organizations ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... Mass., Oct. 22, 2015  Aware, Inc. (NASDAQ: AWRE ), ... results for its third quarter ended September 30, 2015.  ... quarter of 2015 was $4.0 million, a decrease of 33% compared ... in the third quarter of 2015 was $2.2 million, or $0.10 ... diluted share, in the same period a year ago.  ...
Breaking Biology News(10 mins):